Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides

A Non-randomized Multicentre Study for the Evaluation of the Clinical Performance and Safety of the Augmentation-to-surgery and Conservative Treatments for the Degenerative Meniscopathy, With Injection of Polynucleotide Gel

This is a non-randomized multicentre study for the evaluation of the clinical performance and safaty of the augmentation-to-surgery and conservative treatments for the degenerative meniscopathies, with injection of polynucleotide gel.

Study Overview

• Status: Recruiting
• Conditions: Meniscus Lesion; Meniscus Tear
• Intervention / Treatment: Procedure: partial meniscectomy; Device: Condrotide® (polynucleotides gel: class III medical device)

Detailed Description

Meniscal tear plays a significant role among the multitude of ethiologies of knee pain. In the setting of chronic meniscus degeneration, healing potential remains low due to a vascular penetration of less than one-third of the adult meniscus. Currently, both conservative and surgical modalities can be utilized in the treatment of the painful degenerative menisci, and no gold standard treatment has been identified. Polynucleotide gel Condrotide® is a polynucleotide solution, used in case of degenerative painful join pathologies, favouring the physiological mechanism of joint repair because of the capacity to normalize the viscosity of synovial fluid and supposed to improve the joint trophism. The present study aims at evaluating the capacity of the polynucleotide gel injection to stimulate healing and slow down progression of meniscal degeneration, through augmentation-to-surgery and conservative treatments for the degenerative meniscopathies.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Giulia Cattarini Mastelli, Dr.ssa; Phone Number: Tel. (+39) 0184 5111 21; Email: dirmed@mastelli.it

Study Locations

• Belgium
  • Deurne, Belgium, 2100
    • Recruiting
    • Peter Verdonk
    • Contact: Peter Verdonk
• Italy
  • Milan, Italy, 20089
    • Recruiting
    • Elizaveta Kon
    • Contact: Elizaveta Kon, Dr; Phone Number: +390255035186

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female subjects with age between 18 and 65 years
2. Presence of symptomatic degenerative meniscus tear
3. Presence of one of the following unilateral symptoms: pain, catching, or locking of the knee
4. Non responsive to physical therapy for at least 3-4 weeks
5. Be in neutral alignment +/- 5 degrees of the mechanical axis
6. Subject must be physically and mentally willing and able to comply with the study follow-up schedule
7. Subject must sign Ethic committe approved informed consent
8. Subject is willing and able to comply with all study procedures, including visits and diagnostic procedures

Exclusion Criteria:

1. Radiographic osteoarthritis of the knee in any compartment greater than Kellgren-Lawrence (KL) grade 3.
2. Presence of bone marrow edema (BME) at the index knee.
3. Presence of knee instability.
4. Have a varus or valgus knee deformity > 5 degrees.
5. Have meniscal roots tears.
6. Have discoid meniscus.
7. Have patella instability or non-anatomically positioned patella.
8. Have a knee flexion contracture > 10 degrees.
9. Be unable to flex the knee to 90 degrees.
10. Have a leg length discrepancy causing a noticeable limp.
11. Have an active infection or tumor.
12. Have any type of knee joint inflammatory disease including Sjogren's syndrome.
13. Have neuropathic knee osteoarthropathy, also known as Charcot joint.
14. Any disorder or impairment that would interfere with evaluation of outcomes measures, such as neurological, degenerative muscular, psychiatric or cognitive conditions.
15. Participation to another clinical trial or clinical investigation in the previous 3 months.
16. BMI > 35.
17. Prior knee arthroscopy within 6 months of study enrolment.
18. Unable to have an MRI scan.
19. Known allergy, sensitivity or intolerance to any of the components of the investigational device or to products originating from fish.
20. Positive history of human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C virus antibodies.
21. Autoimmune diseases, rheumatoid disease eg. Lupus erythematosus.
22. The subject is currently being treated with radiation and or chemotherapy.
23. Previous or ongoing alcohol abuse or dependence, use of illicit drugs within 1 year prior to enrolment.
24. Patients who are pregnant or planning to become pregnant during the planned period of participation in the study or who are breastfeeding. Women of child-bearing age must consent to use and actually make use of a highly effective contraceptive method, considered acceptable by the investigator, for the whole study duration.
25. Does not agree to participate.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: augmentation to surgery; Patients will be surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel, during an arthroscopic procedure. After 6 weeks the patients attend a second injection session, during an ambulatorial visit. At 8 weeks from the surgery the patients attend the third ambulatorial injection session	Procedure: partial meniscectomy; Arthroscopic procedure; Device: Condrotide® (polynucleotides gel: class III medical device); Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
Experimental: Arm B: conservative treatment; The patients are going to receive three injections session (polynucleotide gel) performed with a time interval of 2 weeks.	Device: Condrotide® (polynucleotides gel: class III medical device); Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Knee Injury Osteoarthritis Outcome Score (KOOS) will be measured	The change of overall KOOS score will be evaluated from baseline (V1) to 6 (V6), 12 (V7), and 24 (V8) months after treatment completion. An improvement of 10 points in the score will be considered success. The KOOS score assesses; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.	24 months (end of follow up)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change of the radiological assessment of the cartilage by a 5-points Likert scale	Likert scale scoring: 0=worsened; 1= not worsened or improved; 2= slightly improved; 3= improved; 4= very much improved). The articular cartilage and meniscal appearance change will be evaluated from baseline (V1) to 6 (V6), 12 (V7), 24 (V8) months after treatment completion (T0).	24 months
The change of the International Knee Documentation Committee (IKDC Questionnaire)	Is a knee-specific patient-reported outcome measure. Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function.	24 months
The change of the Tegner activity score from baseline (V1) to 3 (V5), 6 (V6), 12 (V7), 24 (V8) months after treatment completion (T0).	The Tegner activity scale is a one-item score evaluating work and sports activities on a scale of 0 to 10. Zero represents disability.	24 months
AE and device deficiencies Reporting	Will be evaluated: number and typology of device- or procedure-related serious adverse events (SAEs); the number and typology of all other adverse events (AEs) or SAEs;; the number and typology of device deficiencies (DD)	24 months

Collaborators and Investigators

• Sponsor: Mastelli S.r.l
• Collaborators: Latis S.r.l.
• Investigators: Principal Investigator: Elizaveta Kon, Prof., Plastic surgery IRCCS Humanitas; Principal Investigator: Peter Verdonk, Prof., Monica Ziekenhuizen Antwerpen en Deurne

Study record dates

Study Major Dates

• Study Start (Actual): October 26, 2020
• Primary Completion (Estimated): July 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: March 11, 2022
• First Submitted That Met QC Criteria: April 8, 2022
• First Posted (Actual): April 11, 2022

Study Record Updates

• Last Update Posted (Actual): June 15, 2023
• Last Update Submitted That Met QC Criteria: June 13, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: DDM22M

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No